Trial Profile
Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Allergic asthma; Allergic rhinitis
- Focus Adverse reactions; Pharmacokinetics
- 10 Jul 2012 Trial updated with data from the EUDRA record (EudraCT2008-005048-17)
- 01 Feb 2011 New trial record